文献速递心律失常

导管消融 versus 抗心律失常药物治疗心房颤动的成本效益:CABANA随机临床试验

Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.
PubMed 文献 · Circulation · 2022-06-21

CABANA试验纳入2204例房颤患者,比较导管消融与药物治疗的成本效益。意向性治疗分析显示消融未显著降低主要终点,但改善生活质量和房颤复发。

核心结论

  • 在美国当前医疗价值基准下,基于QALY增量,导管消融治疗房颤较药物治疗具有经济吸引力,但仅基于生命年则不然。

研究设计与样本

  • CABANA随机临床试验的成本效益分析,为预设次要终点,纳入全部2204例患者,采用意向性治疗分析,从美国医疗保健部门视角评估。

主要发现

  • 药物组平均获得12.5生命年和10.7质量调整生命年;消融组对应为12.6生命年和11.0质量调整生命年。

临床怎么用

  • 在评估房颤导管消融的经济性时,应基于QALY而非仅生命年,并参考美国医疗价值基准。

局限性

  • 成本数据部分基于美国患者的前瞻性账单,外推至其他医疗系统需谨慎。
  • 终生成本差异的95%CI跨越0,存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point. METHODS: Medical resource use data were collected for all CABANA patients (N=2204). Costs for hospital-based care were assigned using prospectively collected bills from US patients (n=1171); physician and medication costs were assigned using the Medicare Fee Schedule and National Average Drug Acquisition Costs, respectively. Extrapolated life expectancies were estimated using age-based survival models. Quality-of-life adjustments were based on EQ-5D-based utilities measured during the trial. The primary outcome was the incremental cost-effectiveness ratio, comparing ablation with drug therapy on the basis of intention-to-treat, and assessed from the US health care sector perspective. RESULTS: Costs in the first 3 months averaged $20 794±SD 1069 higher with ablation compared with drug therapy. The cumulative within-trial 5-year cost difference was $19 245 (95% CI, $11 360-$27 170) and the lifetime mean cost difference was $15 516 (95% CI, -$2963 to $35,512) higher with ablation than with drug therapy. The drug therapy arm accrued an average of 12.5 life-years (LYs) and 10.7 quality-adjusted life-years (QALYs). For the ablation arm, the corresponding estimates were 12.6 LYs and 11.0 QALYs. The incremental cost-effectiveness ratio was $57 893 per QALY gained, with 75% of bootstrap replications yielding an incremental cost-effectiveness ratio <$100 000 per QALY gained. With no quality-of-life/utility adjustments, the incremental cost-effectiveness ratio was $183 318 per LY gained. CONCLUSIONS: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chew, Li, Cowper, et al. Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial. Circulation. 2022. PMID: 35726631. doi:10.1161/CIRCULATIONAHA.122.058575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。